ClinicalTrials.gg
CompletedNCT03060577ORION-3Updated Mar 24, 2023Results posted

An Extension Trial of Inclisiran in Participants With Cardiovascular Disease and High Cholesterol

A Phase 2 interventional study of Inclisiran and Evolocumab in Atherosclerotic Cardiovascular Disease, Symptomatic Atherosclerosis and Type2 Diabetes, sponsored by Novartis Pharmaceuticals. Completed at 52 sites in 5 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-03-24.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
382
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 16 studies testing inclisiran in Atherosclerosis — 3 open to participants now, 7 under way, 4 of them phase 3. inclisiran · Atherosclerosis.

Enrollment
10th of 16
382 · median 401
Started
2017
the only one that year
Phase 2
2 of 16
none open now
Registered
2nd of 16
by date
Lead sponsor
9 of 16
Novartis Pharmaceuticals

Among the 16 studies testing inclisiran in Atherosclerosis, this one is the 10th largest by enrollment, is the only one that started in 2017, is one of 2 in phase 2, and was the 2nd registered.

Atherosclerosis

1,519 studies on the registry are indexed under Atherosclerosis; 225 are open to participants now.

Browse Atherosclerosis studies →

Open to participants now

3 of the 16 studies testing inclisiran in Atherosclerosis are open now, in 4 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About inclisiran

inclisiran: first FDA approval 2021 (LEQVIO), first EMA approval 2020. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 161 Atherosclerosis studies recruiting now, 84 (52%) set no upper age limit and 33 (20%) stop at 75 or younger; 16 take children under 18; 33 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 16 studies testing inclisiran in Atherosclerosis, or all of them as a file.
02

Study summary

This clinical study was designed to assess the efficacy, safety, and tolerability of long-term dosing of inclisiran and evolocumab given as subcutaneous injections in participants with high cardiovascular risk and elevated low-density lipoprotein cholesterol (LDL-C).

Read the detailed description

MDCO-PCS-16-01 (ORION-3) was a Phase II, open-label, multicenter, non-randomized, active comparator long term extension study. Total study duration was 4 years from first participant enrolled to the last subject completed. The study consisted of three study periods:

Screening Period: Participants completing study MDCO-PCS-15-01 (ORION-1) were screened for all inclusion and exclusion criteria of study ORION-3.

Treatment Period: Participants fulfilling all eligibility criteria of ORION-3 were enrolled. Participants who received inclisiran in ORION-1 received inclisiran sodium throughout this study up to 4 years (Group 1; Inclisiran-only arm), and participants who received placebo in ORION-1 received evolocumab as open-label comparator up to Day 336, and then transitioned to inclisiran on Day 360 and every 180 days thereafter for up to 4 years (Group 2; Switching arm).

Safety follow up: Participants were followed up for safety during 4 weeks after the last dose of study treatment. Including the Screening Period, the total study duration for a participant was up to 4 years.

03

Conditions studied

  • Atherosclerotic Cardiovascular Disease
  • Symptomatic Atherosclerosis
  • Type2 Diabetes
  • Familial Hypercholesterolemia
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Completion of Study MDCO-PCS-15-01 and no to receiving inclisiran or evolocumab.
  2. Willing and able to give written and before initiation of any study related procedures and willing to comply with all required study procedures.
  3. Willing to self-inject.

Exclusion criteria

Exclusion Criteria:

  1. Any uncontrolled or serious disease, or any medical or surgical condition that may either interfere with participation in the clinical study and/or put the participant at significant risk (according to investigator's [or delegate's] judgment).
  2. An underlying known disease or surgical, physical, or medical condition that, in the opinion of the investigator (or delegate), might interfere with interpretation of the clinical study results.
  3. Serious comorbid disease in which the of the participant is shorter than the duration of the trial (for example, acute systemic infection, cancer, or other serious illnesses).
  4. Active liver disease defined as any known current infectious, neoplastic, or metabolic pathology of the liver; unexplained (ALT) or aspartate aminotransferase (AST) elevation greater than 2 times (ULN); or total elevation greater than 1.5 times ULN at study entry visit.
  5. Females who are pregnant or nursing, or who are of and unwilling to use at least two methods of (for example, oral contraceptives, barrier methods, approved contraceptive implant, long-term injectable contraception, intrauterine device) for the entire duration of the study. Exemptions from this criterion are

    • Women >2 years (defined as 1 year or longer since their last menstrual period) AND more than 55 years of age
    • Postmenopausal women (as defined above) and less than 55 years old with a negative pregnancy test within 24 hours of enrollment
    • Women who are surgically sterilized at least 3 months prior to enrollment
  6. Males who are unwilling to use an acceptable method of birth control during the entire study period (that is, condom with spermicide).
  7. Treatment with medicinal products other than inclisiran or devices within 30 days or five half˗lives, whichever is longer.
  8. Planned use of investigational medicinal products other than inclisiran or devices during the course of the study.
  9. Participants with a history of a serious reaction to evolocumab or any of the
  10. Previous or current treatment (within 90 days of study entry) with monoclonal antibodies directed towards PCSK9.
  11. Any condition that according to the investigator could interfere with the conduct of the study, such as but not limited to:

    • Inappropriate for this study, including participants who are unable to communicate or to cooperate with the investigator.
    • Unable to understand the protocol requirements, instructions and study-related restrictions, the nature, scope, and possible consequences of the study (including participants whose cooperation is doubtful due to drug abuse or alcohol dependency).
    • Unlikely to comply with the protocol requirements, instructions, and study-related restrictions (for example, uncooperative attitude, inability to return for follow-up visits, and improbability of completing the study).
    • Involved with, or a relative of, someone directly involved in the conduct of the study.
    • Any known cognitive impairment (for example, Alzheimer's Disease).
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
382 participants (actual)

Study arms

  • Experimental
    Inclisiran-only

    Participants received subcutaneous injections of inclisiran 300 milligrams (mg) on Day 1 and every 180 days thereafter for up to 4 years.

    Drug: Inclisiran

  • Active comparator
    Switching

    Participants received self-administered subcutaneous injections of evolocumab 140 mg on Day 1 and every 14 days thereafter until Day 336. Then, participants received subcutaneous injections of inclisiran 300 mg on Day 360 and every 180 days thereafter for up to 4 years.

    Drug: Inclisiran · Drug: Evolocumab

Interventions

  • Inclisiran is a synthetic, chemically modified small interfering ribonucleic acid (siRNA) targeting proprotein convertase subtilisin kexin type 9 (PCSK9) messenger ribonucleic acid (mRNA) with a covalently attached triantennary N-acetylgalactosamine (GalNAc) ligand.

    Also known as: ALN-PCSSC

  • Evolocumab is a fully human monoclonal antibody that inhibits PCSK9.

    Also known as: REPATHA

06

What researchers measure

Primary outcomes

  1. Percentage Change in LDL-C From Baseline of the ORION-1 Study to Day 210 in ORION-3 (Inclisiran Arm)

    Percent Change in LDL-C (beta-quantification) from baseline of the ORION-1 Study to Day 210 in ORION-3. A negative percentage score represents a reduction in LDL-C. Change is relative to ORION-1 Baseline, which is defined as the last available record prior to first study drug administration in ORION-1.

    Time frame: Baseline (ORION-1) and Day 210 (ORION-3) (up to 570 days total)

Secondary outcomes

  1. Percentage Change in LDL-C From Baseline of the ORION-1 Study (Inclisiran Arm)

    Percent Change in LDL-C (beta-quantification) from baseline of the ORION-1 Study overtime in ORION-3. A negative percentage score represents a reduction in LDL-C. Changes are relative to ORION-1 Baseline, which is defined as the last available record prior to first study drug administration in ORION-1.

    Time frame: Baseline (ORION-1) and Days 30, 360, 720, 1080 and 1440 (ORION-3) (up to 390, 720, 1080, 1440 and 1800 days total, respectively)

  2. Absolute Change in LDL-C From Baseline of the ORION-1 Study (Inclisiran Arm)

    Absolute Change in LDL-C (beta-quantification) from baseline of the ORION-1 Study overtime in ORION-3. A negative score represents a reduction in LDL-C. Changes are relative to ORION-1 Baseline, which is defined as the last available record prior to first study drug administration in ORION-1.

    Time frame: Baseline (ORION-1) and Days 30, 360, 720, 1080 and 1440 (ORION-3) (up to 390, 720, 1080, 1440 and 1800 days total, respectively)

  3. Percentage Change in PCSK9 Levels From Baseline of the ORION-1 Study (Inclisiran Arm)

    Percent Change in PCSK9 from baseline of the ORION-1 Study overtime in ORION-3. A negative percentage score represents a reduction in PCSK9. Changes are relative to ORION-1 Baseline, which is defined as the last available record prior to first study drug administration in ORION-1.

    Time frame: Baseline (ORION-1) and Days 30, 360, 720 and 1440 (ORION-3) (up to 390, 720, 1080 and 1800 days total, respectively)

  4. Absolute Change in PCSK9 Levels From Baseline of the ORION-1 Study (Inclisiran Arm)

    Absolute Change in PCSK9 from baseline of the ORION-1 Study overtime in ORION-3. A negative score represents a reduction in PCSK9. Changes are relative to ORION-1 Baseline, which is defined as the last available record prior to first study drug administration in ORION-1.

    Time frame: Baseline (ORION-1) and Days 30, 360, 720 and 1440 (ORION-3) (up to 390, 720, 1080 and 1800 days total, respectively)

  5. Percentage Change in Triglycerides From Baseline of the ORION-1 Study (Inclisiran Arm)

    Percent Change in Triglycerides from baseline of the ORION-1 Study overtime in ORION-3. A negative percentage score represents a reduction in Triglycerides. Changes are relative to ORION-1 Baseline, which is defined as the last available record prior to first study drug administration in ORION-1.

    Time frame: Baseline (ORION-1) and Days 30, 210 and 1440 (ORION-3) (up to 390, 570 and 1800 days total, respectively)

  6. Absolute Change in Triglycerides From Baseline of the ORION-1 Study (Inclisiran Arm)

    Absolute Change in Triglycerides from baseline of the ORION-1 Study overtime in ORION-3. A negative score represents a reduction in Triglycerides. Changes are relative to ORION-1 Baseline, which is defined as the last available record prior to first study drug administration in ORION-1.

    Time frame: Baseline (ORION-1) and Days 30, 210 and 1440 (ORION-3) (up to 390, 570 and 1800 days total, respectively)

  7. Percentage Change in Apolipoprotein B From Baseline of the ORION-1 Study (Inclisiran Arm)

    Percent Change in Apolipoprotein B from baseline of the ORION-1 Study overtime in ORION-3. A negative percentage score represents a reduction in Apolipoprotein B. Changes are relative to ORION-1 Baseline, which is defined as the last available record prior to first study drug administration in ORION-1.

    Time frame: Baseline (ORION-1) and Days 30, 210 and 1440 (ORION-3) (up to 390, 570 and 1800 days total, respectively)

  8. Absolute Change in Apolipoprotein B From Baseline of the ORION-1 Study (Inclisiran Arm)

    Absolute Change in Apolipoprotein B from baseline of the ORION-1 Study overtime in ORION-3. A negative score represents a reduction in Apolipoprotein B. Changes are relative to ORION-1 Baseline, which is defined as the last available record prior to first study drug administration in ORION-1.

    Time frame: Baseline (ORION-1) and Days 30, 210 and 1440 (ORION-3) (up to 390, 570 and 1800 days total, respectively)

  9. Percentage Change in Lipoprotein-a From Baseline of the ORION-1 Study (Inclisiran Arm)

    Percent Change in Lipoprotein-a from baseline of the ORION-1 Study overtime in ORION-3. A negative percentage score represents a reduction in Lipoprotein-a. Changes are relative to ORION-1 Baseline, which is defined as the last available record prior to first study drug administration in ORION-1.

    Time frame: Baseline (ORION-1) and Days 30, 210 and 1440 (ORION-3) (up to 390, 570 and 1800 days total, respectively)

  10. Absolute Change in Lipoprotein-a From Baseline of the ORION-1 Study (Inclisiran Arm)

    Absolute Change in Lipoprotein-a from baseline of the ORION-1 Study overtime in ORION-3. A negative score represents a reduction in Lipoprotein-a. Changes are relative to ORION-1 Baseline, which is defined as the last available record prior to first study drug administration in ORION-1.

    Time frame: Baseline (ORION-1) and Days 30, 210 and 1440 (ORION-3) (up to 390, 570 and 1800 days total, respectively)

  11. Number of Participants With ≥50% LDL-C Reduction From Baseline of the ORION-1 Study (Inclisiran Arm)

    Number of Participants with ≥50% LDL-C (beta-quantification) Reduction from baseline of the ORION-1 Study overtime in ORION-3. Changes are relative to ORION-1 Baseline, which is defined as the last available record prior to first study drug administration in ORION-1.

    Time frame: Baseline (ORION-1) and Days 30, 360, 720 and 1440 (ORION-3) (up to 390, 720, 1080 and 1800 days total, respectively)

  12. Number of Participants Reaching on Treatment LDL-C Levels of <25 mg/dL, <50 mg/dL, <70 mg/dL, and <100 mg/dL (Inclisiran Arm)

    Individual responsiveness to inclisiran is defined as the number of Participants Reaching on Treatment LDL-C Levels of \<25 mg/dL, \<50 mg/dL, \<70 mg/dL, and \<100 mg/dL at any time point.

    Time frame: From the start of treatment in ORION-3 to 90 days after end of treatment, assessed up to maximum duration of 4 years

07

Results

Posted Mar 24, 2023

Participant flow

Participants were recruited from 51 sites in 5 countries.

Participant flow — Overall Study
MilestoneInclisiran-onlySwitching
Started29092
Safety analysis set28490
Completed23380
Not completed5712
Withdrew: Withdrawal by subject255
Withdrew: Physician decision43
Withdrew: Lost to follow-up30
Withdrew: Death71
Withdrew: Adverse event91
Withdrew: Inclusion/exclusion10
Withdrew: Other82

Outcome measures

PrimaryPercentage Change in LDL-C From Baseline of the ORION-1 Study to Day 210 in ORION-3 (Inclisiran Arm)

Percent Change in LDL-C (beta-quantification) from baseline of the ORION-1 Study to Day 210 in ORION-3. A negative percentage score represents a reduction in LDL-C. Change is relative to ORION-1 Baseline, which is defined as the last available record prior to first study drug administration in ORION-1.

Time frame:
Baseline (ORION-1) and Day 210 (ORION-3) (up to 570 days total)
Reported as:
Mean · Percentage Change
Percentage Change in LDL-C From Baseline of the ORION-1 Study to Day 210 in ORION-3 (Inclisiran Arm)
Percentage ChangeInclisiran-only
Percentage Change in LDL-C From Baseline of the ORION-1 Study to Day 210 in ORION-3 (Inclisiran Arm)-47.48 (-50.69 to -44.27)
SecondaryPercentage Change in LDL-C From Baseline of the ORION-1 Study (Inclisiran Arm)

Percent Change in LDL-C (beta-quantification) from baseline of the ORION-1 Study overtime in ORION-3. A negative percentage score represents a reduction in LDL-C. Changes are relative to ORION-1 Baseline, which is defined as the last available record prior to first study drug administration in ORION-1.

Time frame:
Baseline (ORION-1) and Days 30, 360, 720, 1080 and 1440 (ORION-3) (up to 390, 720, 1080, 1440 and 1800 days total, respectively)
Reported as:
Mean · Percentage Change
Percentage Change in LDL-C From Baseline of the ORION-1 Study (Inclisiran Arm)
Percentage ChangeInclisiran-only
Day 30-49.43 (-52.27 to -46.58)
Day 360-37.14 (-40.95 to -33.32)
Day 720-38.43 (-41.75 to -35.11)
Day 1080-51.07 (-54.75 to -47.39)
Day 1440-46.74 (-50.71 to -42.78)
SecondaryAbsolute Change in LDL-C From Baseline of the ORION-1 Study (Inclisiran Arm)

Absolute Change in LDL-C (beta-quantification) from baseline of the ORION-1 Study overtime in ORION-3. A negative score represents a reduction in LDL-C. Changes are relative to ORION-1 Baseline, which is defined as the last available record prior to first study drug administration in ORION-1.

Time frame:
Baseline (ORION-1) and Days 30, 360, 720, 1080 and 1440 (ORION-3) (up to 390, 720, 1080, 1440 and 1800 days total, respectively)
Reported as:
Mean · mg/dL
Absolute Change in LDL-C From Baseline of the ORION-1 Study (Inclisiran Arm)
mg/dLInclisiran-only
Day 30-62.51 (-66.76 to -58.25)
Day 360-47.96 (-52.56 to -43.35)
Day 720-49.44 (-54.25 to -44.64)
Day 1080-63.34 (-68.76 to -57.92)
Day 1440-60.04 (-65.81 to -54.27)
SecondaryPercentage Change in PCSK9 Levels From Baseline of the ORION-1 Study (Inclisiran Arm)

Percent Change in PCSK9 from baseline of the ORION-1 Study overtime in ORION-3. A negative percentage score represents a reduction in PCSK9. Changes are relative to ORION-1 Baseline, which is defined as the last available record prior to first study drug administration in ORION-1.

Time frame:
Baseline (ORION-1) and Days 30, 360, 720 and 1440 (ORION-3) (up to 390, 720, 1080 and 1800 days total, respectively)
Reported as:
Mean · Percentage Change
Percentage Change in PCSK9 Levels From Baseline of the ORION-1 Study (Inclisiran Arm)
Percentage ChangeInclisiran-only
Day 30-71.80 (-73.17 to -70.44)
Day 360-63.79 (-65.79 to -61.80)
Day 720-62.17 (-64.46 to -59.88)
Day 1440-69.54 (-71.19 to -67.89)
SecondaryAbsolute Change in PCSK9 Levels From Baseline of the ORION-1 Study (Inclisiran Arm)

Absolute Change in PCSK9 from baseline of the ORION-1 Study overtime in ORION-3. A negative score represents a reduction in PCSK9. Changes are relative to ORION-1 Baseline, which is defined as the last available record prior to first study drug administration in ORION-1.

Time frame:
Baseline (ORION-1) and Days 30, 360, 720 and 1440 (ORION-3) (up to 390, 720, 1080 and 1800 days total, respectively)
Reported as:
Mean · ug/L
Absolute Change in PCSK9 Levels From Baseline of the ORION-1 Study (Inclisiran Arm)
ug/LInclisiran-only
Day 30-314.07 (-328.69 to -299.45)
Day 360-280.88 (-295.71 to -266.06)
Day 720-275.78 (-291.91 to -259.64)
Day 1440-314.34 (-331.22 to -297.46)
SecondaryPercentage Change in Triglycerides From Baseline of the ORION-1 Study (Inclisiran Arm)

Percent Change in Triglycerides from baseline of the ORION-1 Study overtime in ORION-3. A negative percentage score represents a reduction in Triglycerides. Changes are relative to ORION-1 Baseline, which is defined as the last available record prior to first study drug administration in ORION-1.

Time frame:
Baseline (ORION-1) and Days 30, 210 and 1440 (ORION-3) (up to 390, 570 and 1800 days total, respectively)
Reported as:
Mean · Percentage Change
Percentage Change in Triglycerides From Baseline of the ORION-1 Study (Inclisiran Arm)
Percentage ChangeInclisiran-only
Day 30-1.71 (-6.42 to 3.00)
Day 210-3.35 (-9.12 to 2.41)
Day 14400.73 (-8.23 to 9.69)
SecondaryAbsolute Change in Triglycerides From Baseline of the ORION-1 Study (Inclisiran Arm)

Absolute Change in Triglycerides from baseline of the ORION-1 Study overtime in ORION-3. A negative score represents a reduction in Triglycerides. Changes are relative to ORION-1 Baseline, which is defined as the last available record prior to first study drug administration in ORION-1.

Time frame:
Baseline (ORION-1) and Days 30, 210 and 1440 (ORION-3) (up to 390, 570 and 1800 days total, respectively)
Reported as:
Mean · mg/dL
Absolute Change in Triglycerides From Baseline of the ORION-1 Study (Inclisiran Arm)
mg/dLInclisiran-only
Day 30-14.61 (-22.15 to -7.08)
Day 210-11.96 (-23.78 to -0.14)
Day 1440-14.83 (-25.75 to -3.90)
SecondaryPercentage Change in Apolipoprotein B From Baseline of the ORION-1 Study (Inclisiran Arm)

Percent Change in Apolipoprotein B from baseline of the ORION-1 Study overtime in ORION-3. A negative percentage score represents a reduction in Apolipoprotein B. Changes are relative to ORION-1 Baseline, which is defined as the last available record prior to first study drug administration in ORION-1.

Time frame:
Baseline (ORION-1) and Days 30, 210 and 1440 (ORION-3) (up to 390, 570 and 1800 days total, respectively)
Reported as:
Mean · Percentage Change
Percentage Change in Apolipoprotein B From Baseline of the ORION-1 Study (Inclisiran Arm)
Percentage ChangeInclisiran-only
Day 30-40.43 (-42.57 to -38.29)
Day 210-36.65 (-39.06 to -34.23)
Day 1440-33.66 (-37.18 to -30.15)
SecondaryAbsolute Change in Apolipoprotein B From Baseline of the ORION-1 Study (Inclisiran Arm)

Absolute Change in Apolipoprotein B from baseline of the ORION-1 Study overtime in ORION-3. A negative score represents a reduction in Apolipoprotein B. Changes are relative to ORION-1 Baseline, which is defined as the last available record prior to first study drug administration in ORION-1.

Time frame:
Baseline (ORION-1) and Days 30, 210 and 1440 (ORION-3) (up to 390, 570 and 1800 days total, respectively)
Reported as:
Mean · mg/dL
Absolute Change in Apolipoprotein B From Baseline of the ORION-1 Study (Inclisiran Arm)
mg/dLInclisiran-only
Day 30-42.63 (-45.22 to -40.04)
Day 210-38.36 (-41.19 to -35.54)
Day 1440-36.26 (-40.01 to -32.52)
SecondaryPercentage Change in Lipoprotein-a From Baseline of the ORION-1 Study (Inclisiran Arm)

Percent Change in Lipoprotein-a from baseline of the ORION-1 Study overtime in ORION-3. A negative percentage score represents a reduction in Lipoprotein-a. Changes are relative to ORION-1 Baseline, which is defined as the last available record prior to first study drug administration in ORION-1.

Time frame:
Baseline (ORION-1) and Days 30, 210 and 1440 (ORION-3) (up to 390, 570 and 1800 days total, respectively)
Reported as:
Mean · Percentage Change
Percentage Change in Lipoprotein-a From Baseline of the ORION-1 Study (Inclisiran Arm)
Percentage ChangeInclisiran-only
Day 30-15.88 (-19.48 to -12.28)
Day 2109.29 (4.42 to 14.16)
Day 1440-5.24 (-9.86 to -0.61)
SecondaryAbsolute Change in Lipoprotein-a From Baseline of the ORION-1 Study (Inclisiran Arm)

Absolute Change in Lipoprotein-a from baseline of the ORION-1 Study overtime in ORION-3. A negative score represents a reduction in Lipoprotein-a. Changes are relative to ORION-1 Baseline, which is defined as the last available record prior to first study drug administration in ORION-1.

Time frame:
Baseline (ORION-1) and Days 30, 210 and 1440 (ORION-3) (up to 390, 570 and 1800 days total, respectively)
Reported as:
Mean · nmol/L
Absolute Change in Lipoprotein-a From Baseline of the ORION-1 Study (Inclisiran Arm)
nmol/LInclisiran-only
Day 30-8.52 (-12.25 to -4.79)
Day 210-4.94 (-8.67 to -1.20)
Day 1440-4.78 (-9.63 to 0.06)
SecondaryNumber of Participants With ≥50% LDL-C Reduction From Baseline of the ORION-1 Study (Inclisiran Arm)

Number of Participants with ≥50% LDL-C (beta-quantification) Reduction from baseline of the ORION-1 Study overtime in ORION-3. Changes are relative to ORION-1 Baseline, which is defined as the last available record prior to first study drug administration in ORION-1.

Time frame:
Baseline (ORION-1) and Days 30, 360, 720 and 1440 (ORION-3) (up to 390, 720, 1080 and 1800 days total, respectively)
Reported as:
Count of participants · Participants
Number of Participants With ≥50% LDL-C Reduction From Baseline of the ORION-1 Study (Inclisiran Arm)
ParticipantsInclisiran-only
Day 30161
Day 36099
Day 72097
Day 1440122
SecondaryNumber of Participants Reaching on Treatment LDL-C Levels of <25 mg/dL, <50 mg/dL, <70 mg/dL, and <100 mg/dL (Inclisiran Arm)

Individual responsiveness to inclisiran is defined as the number of Participants Reaching on Treatment LDL-C Levels of \<25 mg/dL, \<50 mg/dL, \<70 mg/dL, and \<100 mg/dL at any time point.

Time frame:
From the start of treatment in ORION-3 to 90 days after end of treatment, assessed up to maximum duration of 4 years
Reported as:
Count of participants · Participants
Number of Participants Reaching on Treatment LDL-C Levels of <25 mg/dL, <50 mg/dL, <70 mg/dL, and <100 mg/dL (Inclisiran Arm)
ParticipantsInclisiran-only
LDL-C level <25 mg/dL82
LDL-C level <50 mg/dL175
LDL-C level <70 mg/dL225
LDL-C level <100 mg/dL265

Adverse events

Collected over Adverse events were reported from first dose of study treatment in ORION-3 up to end of study visit, assessed up to maximum duration of 4 years.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Inclisiran Only Arm7/284 (2.5%)104/284 (36.6%)271/284 (95.4%)
Switching Arm up to Day 360 Visit0/90 (0%)16/90 (17.8%)78/90 (86.7%)
Switching Arm After Day 360 Visit1/87 (1.1%)30/87 (34.5%)77/87 (88.5%)
Most frequent serious events
Showing 10 of 149
Most frequent serious events
EventInclisiran Only ArmSwitching Arm up to Day 360 VisitSwitching Arm After Day 360 Visit
Coronary artery diseaseCardiac disorders4/2841/903/87
Angina pectorisCardiac disorders7/2840/901/87
Acute myocardial infarctionCardiac disorders4/2841/902/87
Transient ischaemic attackNervous system disorders4/2840/902/87
Hypertensive urgencyVascular disorders0/2840/902/87
Haemorrhoidal haemorrhageGastrointestinal disorders0/2842/900/87
COVID-19Infections and infestations6/2840/901/87
OsteoarthritisMusculoskeletal and connective tissue disorders6/2840/900/87
Angina unstableCardiac disorders5/2841/900/87
Atrial fibrillationCardiac disorders4/2841/901/87
Most frequent other events
Showing 10 of 793
Most frequent other events
EventInclisiran Only ArmSwitching Arm up to Day 360 VisitSwitching Arm After Day 360 Visit
HypertensionVascular disorders42/2842/9017/87
NasopharyngitisInfections and infestations55/2846/9013/87
Back painMusculoskeletal and connective tissue disorders28/2841/9013/87
ArthralgiaMusculoskeletal and connective tissue disorders40/28410/9010/87
Urinary tract infectionInfections and infestations37/2846/907/87
InfluenzaInfections and infestations36/2846/9010/87
FatigueGeneral disorders23/2843/9010/87
Diabetes mellitusMetabolism and nutrition disorders32/2840/906/87
DiarrhoeaGastrointestinal disorders17/2843/909/87
HeadacheNervous system disorders21/2848/907/87

Baseline characteristics

All enrolled participants

Age, Continuous
Age, Continuous(Year)Inclisiran-onlySwitchingTotal
Mean63.3 ± 11.1461.9 ± 10.5663.0 ± 11.01
Sex: Female, Male
Sex: Female, Male(Participants)Inclisiran-onlySwitchingTotal
Female10237139
Male18855243
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Inclisiran-onlySwitchingTotal
Hispanic or Latino15722
Not Hispanic or Latino27585360
Unknown or Not Reported000
08

Study locations

52 sites
  • Novartis Investigative Site
    Jacksonville, Florida 32216, United States
  • Novartis Investigative Site
    Indianapolis, Indiana 46260, United States
  • Novartis Investigative Site
    New York, New York 10029, United States
  • Novartis Investigative Site
    Cincinnati, Ohio 45229, United States
  • Novartis Investigative Site
    Cincinnati, Ohio 45246, United States
  • Novartis Investigative Site
    Greenville, Tennessee 37745, United States
  • Novartis Investigative Site
    Amarillo, Texas 79106, United States
  • Novartis Investigative Site
    Richmond, Virginia 23294, United States
  • Novartis Investigative Site
    Vancouver, British Columbia V6Z 1Y6, Canada
  • Novartis Investigative Site
    Winnipeg, Manitoba R2H 2A6, Canada
  • Novartis Investigative Site
    Brampton, Ontario L6Z 4N5, Canada
  • Novartis Investigative Site
    London, Ontario N6A 4G5, Canada
  • Novartis Investigative Site
    Toronto, Ontario M5C 2T2, Canada
  • Novartis Investigative Site
    Chicoutimi, Quebec G7H 7K9, Canada
  • Novartis Investigative Site
    Montreal, Quebec H2W 1R7, Canada
  • Novartis Investigative Site
    Sherbrooke, Quebec J1H 5N4, Canada
  • Novartis Investigative Site
    Quebec, G1V 4G5, Canada
  • Novartis Investigative Site
    Quebec, G1V 4W2, Canada
  • Novartis Investigative Site
    St Johns, A1B 3V6, Canada
  • Novartis Investigative Site
    Berlin, 12203, Germany
  • Novartis Investigative Site
    Essen, 45355, Germany
  • Novartis Investigative Site
    Frankfurt, 60590, Germany
  • Novartis Investigative Site
    Heidelberg, 69120, Germany
  • Novartis Investigative Site
    Munich, 80636, Germany
  • Novartis Investigative Site
    Rotterdam, The Netherlands 3021 HC, Netherlands
  • Novartis Investigative Site
    Leiden, Zuid-Holland 2333 ZA, Netherlands
  • Novartis Investigative Site
    Amsterdam, 1105 AZ, Netherlands
  • Novartis Investigative Site
    Den Haag, 2545 CH, Netherlands
  • Novartis Investigative Site
    Deventer, 7416 SE, Netherlands
  • Novartis Investigative Site
    Eindhoven, 5611NJ, Netherlands
  • Novartis Investigative Site
    Goes, 4462 RA, Netherlands
  • Novartis Investigative Site
    Hoogeveen, 7909 AA, Netherlands
  • Novartis Investigative Site
    Hoogezand, 9603 AE, Netherlands
  • Novartis Investigative Site
    Hoorn, 1624 NP, Netherlands
  • Novartis Investigative Site
    Utrecht, 3582 KE, Netherlands
  • Novartis Investigative Site
    Utrecht, 3584 CX, Netherlands
  • Novartis Investigative Site
    Venlo, 5912 BL, Netherlands
  • Novartis Investigative Site
    Zwijndrecht, 3331 LZ, Netherlands
  • Novartis Investigative Site
    Fowey, Cornwall PL23 1DT, United Kingdom
  • Novartis Investigative Site
    Liskeard, Cornwall PL14 3XA, United Kingdom
  • Novartis Investigative Site
    Penzance, Cornwall TR18 AJH, United Kingdom
  • Novartis Investigative Site
    St Austell, Cornwall PL26 7RL, United Kingdom
  • Novartis Investigative Site
    Torpoint, Cornwall PL11 2TB, United Kingdom
  • Novartis Investigative Site
    Birmingham, B15 2TH, United Kingdom
  • Novartis Investigative Site
    Edinburgh, ED16 4SA, United Kingdom
  • Novartis Investigative Site
    Exeter, EX2 5DW, United Kingdom
  • Novartis Investigative Site
    High Wycombe, HP16 9QJ, United Kingdom
  • Novartis Investigative Site
    London, NW3 2QG, United Kingdom
  • Novartis Investigative Site
    Manchester, M13 9WL, United Kingdom
  • Novartis Investigative Site
    Newcastle Upon Tyme, NE4 4LP, United Kingdom
  • Novartis Investigative Site
    Plymouth, PL5 3JB, United Kingdom
  • Novartis Investigative Site
    Worcester, WR5 1DD, United Kingdom
09

References and documents

Publications

  • Warden BA, Duell PB. Inclisiran: A Novel Agent for Lowering Apolipoprotein B-containing Lipoproteins. J Cardiovasc Pharmacol. 2021 Aug 1;78(2):e157-e174. doi: 10.1097/FJC.0000000000001053. PubMed 33990512 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Novartis is committed to sharing access to patient-level data and supporting clinical documents from eligible studies with qualified external researchers. Requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to protect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2017 to primary completion in Dec 2021, 55 months.

Results were first posted in Mar 2023, 1 year 3 months after primary completion.

Of 46 phase 2 interventional studies under Atherosclerosis, half reached primary completion within 30 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 59. This study's 55 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 17, 2017
First posted
Feb 23, 2017
StartActual
Apr 27, 2017
Primary completionActual
Dec 17, 2021
CompletionActual
Dec 17, 2021
Results first posted
Mar 24, 2023
Last update
Mar 24, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 24, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03060577
Responsible party
Sponsor
First posted
Feb 23, 2017
Start date
Apr 27, 2017
Primary completion
Dec 17, 2021
Completion
Dec 17, 2021
Results posted
Mar 24, 2023
Last update
Mar 24, 2023

Study contacts

Kausik Ray, MD
principal investigator · Imperial College London

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Inclisiran

Start the discussion